APA (7th ed.) Citation
(2026). PACIFIC‐5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC. Thoracic Cancer.
Chicago Style (17th ed.) Citation
"PACIFIC‐5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC." Thoracic Cancer 2026.
MLA (9th ed.) Citation
"PACIFIC‐5 Trial: Refining Patient Selection for Consolidation Durvalumab in Unresectable Stage III NSCLC." Thoracic Cancer, 2026.
Warning: These citations may not always be 100% accurate.